From Immune Dysregulations to Therapeutic Perspectives in Myelodysplastic Syndromes: A Review

被引：7

作者：

Comont, Thibault ^{[1
,2
,3
]}

Treiner, Emmanuel ^{[3
,4
,5
]}

Vergez, Francois ^{[2
,3
,6
]}

机构：

[1] Toulouse Univ Hosp, CHU Toulouse, Dept Internal Med, IUCT Oncopole, F-31300 Toulouse, France

[2] CNRS, Canc Res Ctr Toulouse, UMR 1037, INSERM,ERL5294, F-31100 Toulouse, France

[3] Univ Toulouse III Paul Sabatier, Sch Med, F-31062 Toulouse, France

[4] Toulouse Univ Hosp, Lab Immunol, CHU Toulouse, F-31300 Toulouse, France

[5] Infinity, Inserm UMR1291, F-31000 Toulouse, France

[6] Toulouse Univ Hosp, CHU Toulouse, Lab Hematol, IUCT Oncopole, F-31300 Toulouse, France

来源：

DIAGNOSTICS | 2021年 / 11卷 / 11期

关键词：

myelodysplastic syndromes; immune; inflammation; T-cell; ACUTE MYELOID-LEUKEMIA; WT1 PEPTIDE VACCINATION; REGULATORY T-CELLS; HEMATOPOIETIC PROGENITOR CELLS; TRANSFUSION-DEPENDENT PATIENTS; PROGNOSTIC SCORING SYSTEM; NECROSIS-FACTOR-ALPHA; CLONAL HEMATOPOIESIS; BONE-MARROW; DENDRITIC CELLS;

D O I：

10.3390/diagnostics11111982

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The pathophysiology of myelodysplastic syndromes (MDSs) is complex and often includes immune dysregulation of both the innate and adaptive immune systems. Whereas clonal selection mainly involves smoldering inflammation, a cellular immunity dysfunction leads to increased apoptosis and blast proliferation. Addressing immune dysregulations in MDS is a recent concept that has allowed the identification of new therapeutic targets. Several approaches targeting the different actors of the immune system have therefore been developed. However, the results are very heterogeneous, indicating the need to improve our understanding of the disease and interactions between chronic inflammation, adaptive dysfunction, and somatic mutations. This review highlights current knowledge of the role of immune dysregulation in MDS pathophysiology and the field of new drugs.

引用

页数：19

共 183 条

[21] Th17 and Foxp3+ T regulatory cell dynamics and distribution in myelodysplastic syndromes [J].

Bouchliou, Irene ;

Miltiades, Paraskevi ;

Nakou, Evangelia ;

Spanoudakis, Emmanouil ;

Goutzouvelidis, Aggelos ;

Vakalopoulou, Sofia ;

Garypidou, Vasilia ;

Kotoula, Vasiliki ;

Bourikas, George ;

Tsatalas, Costas ;

Kotsianidis, Ioannis .

CLINICAL IMMUNOLOGY, 2011, 139 (03) :350-359

[22] Therapeutic options in VEXAS syndrome: insights from a retrospective series [J].

Bourbon, Estelle ;

Heiblig, Mael ;

Valentin, Mathieu Gerfaud ;

Barba, Thomas ;

Durel, Cecile-Audrey ;

Lega, Jean Christophe ;

Barraco, Fiorenza ;

Seve, Pascal ;

Jamilloux, Yvan ;

Sujobert, Pierre .

BLOOD, 2021, 137 (26) :3682-3684

[23] WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides [J].

Brayer, Jason ;

Lancet, Jeffrey E. ;

Powers, John ;

List, Alan ;

Balducci, Lodovico ;

Komrokji, Rami ;

Pinilla-Ibarz, Javier .

AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (07) :602-607

[24] Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study [J].

Brunner, Andrew M. ;

Esteve, Jordi ;

Porkka, Kimmo ;

Knapper, Steve ;

Vey, Norbert ;

Scholl, Sebastian ;

Garcia-Manero, Guillermo ;

Wermke, Martin ;

Janssen, Jeroen ;

Traer, Elie ;

Loo, Sun ;

Narayan, Rupa ;

Tovar, Natalia ;

Kontro, Mika ;

Ottmann, Oliver ;

Naidu, Purushotham ;

Kurtulus, Sema ;

Makofske, Jessica ;

Liao, Serena ;

Mohammed, Anisa ;

Sabatos-Peyton, Catherine A. ;

Rinne, Mikael L. ;

Borate, Uma ;

Wei, Andrew H. .

BLOOD, 2020, 136

[25] Myelodysplastic Syndromes [J].

Cazzola, Mario .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (14) :1358-1374

[26] Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies [J].

Chao, Mark P. ;

Takimoto, Chris H. ;

Feng, Dong Dong ;

McKenna, Kelly ;

Gip, Phung ;

Liu, Jie ;

Volkmer, Jens-Peter ;

Weissman, Irving L. ;

Majeti, Ravindra .

FRONTIERS IN ONCOLOGY, 2020, 9

[27] Treatment of myelodysplastic syndrome with cyclosporin A [J].

Chen, Shuchang ;

Jiang, Bin ;

Da, Wanming ;

Gong, Ming ;

Guana, Mei .

INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 85 (01) :11-17

[28] Induction of myelodysplasia by myeloid-derived suppressor cells [J].

Chen, Xianghong ;

Eksioglu, Erika A. ;

Zhou, Junmin ;

Zhang, Ling ;

Djeu, Julie ;

Fortenbery, Nicole ;

Epling-Burnette, Pearlie ;

Van Bijnen, Sandra ;

Dolstra, Harry ;

Cannon, John ;

Youn, Je-in ;

Donatelli, Sarah S. ;

Qin, Dahui ;

De Witte, Theo ;

Tao, Jianguo ;

Wang, Huaquan ;

Cheng, Pingyan ;

Gabrilovich, Dmitry I. ;

List, Alan ;

Wei, Sheng .

JOURNAL OF CLINICAL INVESTIGATION, 2013, 123 (11) :4595-4611

[29] S100A9-induced overexpression of PD-1/PD-L1 contributes to ineffective hematopoiesis in myelodysplastic syndromes [J].

Cheng, Pinyang ;

Eksioglu, Erika A. ;

Chen, Xianghong ;

Kandell, Wendy ;

Thu Le Trinh ;

Cen, Ling ;

Qi, Jin ;

Sallman, David A. ;

Zhang, Yu ;

Tu, Nhan ;

Adams, William A. ;

Zhang, Chunze ;

Liu, Jinhong ;

Cleveland, John L. ;

List, Alan F. ;

Wei, Sheng .

LEUKEMIA, 2019, 33 (08) :2034-2046

[30] Phase II study of azacitidine with pembrolizumab in patients with intermediate-1 or higher-risk myelodysplastic syndrome [J].

Chien, Kelly S. ;

Kim, Kunhwa ;

Nogueras-Gonzalez, Graciela M. ;

Borthakur, Gautam ;

Naqvi, Kiran ;

Daver, Naval G. ;

Montalban-Bravo, Guillermo ;

Cortes, Jorge E. ;

DiNardo, Courtney D. ;

Jabbour, Elias ;

Alvarado, Yesid ;

Andreeff, Michael ;

Bose, Prithviraj ;

Jain, Nitin ;

Kadia, Tapan M. ;

Huang, Xuelin ;

Sheppard, Kimberly B. ;

Klingner-Winton, Cheri ;

Pierce, Sherry A. ;

Dong, Xiao Qin ;

Soltysiak, Kelly A. ;

Kantarjian, Hagop M. ;

Garcia-Manero, Guillermo .

BRITISH JOURNAL OF HAEMATOLOGY, 2021, 195 (03) :378-387

← 1 2 3 4 5 6 7 8 9 10 →